Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
70.65
-0.80 (-1.12%)
At close: Aug 26, 2026, 4:00 PM EDT
71.00
+0.35 (0.50%)
Pre-market: Aug 27, 2026, 8:15 AM EDT
Tarsus Pharmaceuticals Employees
Tarsus Pharmaceuticals had 370 employees as of December 31, 2025. The number of employees increased by 47 or 14.55% compared to the previous year.
Employees
370
Change (1Y)
47
Growth (1Y)
14.55%
Revenue / Employee
$1,638,732
Profits / Employee
-$125,611
Market Cap
3.10B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 370 | 47 | 14.55% |
| Dec 31, 2024 | 323 | 79 | 32.38% |
| Dec 31, 2023 | 244 | 157 | 180.46% |
| Dec 31, 2022 | 87 | 41 | 89.13% |
| Dec 31, 2021 | 46 | 26 | 130.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AbCellera Biologics | 562 |
| Arcutis Biotherapeutics | 354 |
| Structure Therapeutics | 281 |
| Immunome | 247 |
| Alumis | 239 |
| uniQure | 221 |
| Celldex Therapeutics | 198 |
| Disc Medicine | 165 |
TARS News
- 3 days ago - Alkeus Pharmaceuticals Announces Japan Ministry of Health, Labour and Welfare (MHLW) Has Granted Orphan Drug Designation to Gildeuretinol for Stargardt Disease - GlobeNewsWire
- 10 days ago - Tarsus Pharmaceuticals price target raised to $100 from $97 at Oppenheimer - TheFly
- 17 days ago - Tarsus Pharmaceuticals price target raised to $100 from $98 at Mizuho - TheFly
- 20 days ago - Tarsus to acquire Alkeus Pharmaceuticals for $450M upfront, up to $800M total - TheFly
- 21 days ago - Tarsus Pharmaceuticals reports Q2 EPS (43c), consensus (20c) - TheFly
- 21 days ago - Tarsus Pharmaceuticals announces $125M private placement - TheFly
- 21 days ago - Tarsus Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts
- 21 days ago - Tarsus Pharmaceuticals Earnings release: Q2 2026 - Filings